Company intelligence
OSE Immunotherapeutics
Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients
About OSE Immunotherapeutics
OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f
Verified activity
Signals from OSE Immunotherapeutics
7 published signals
Products & Services
OSE Immunotherapeutics is preparing the next steps for Lusvertikimab development, including a subcutaneous formulation and exploration in other inflammatory diseases, including pouchitis.
Reported by OSE Immunotherapeutics
Products & Services
OSE Immunotherapeutics completed phase 2 CoTikiS study in 136 patients with moderate to severe rectocolitis, achieving its primary evaluation criterion.
Reported by OSE Immunotherapeutics
Presence & Recognition
OSE Immunotherapeutics was featured in the French Tech Good Morning Business chronique by Brigitte Boucher and Anthony Morel.
Reported by OSE Immunotherapeutics
Presence & Recognition
OSE Immunotherapeutics returned to Tedopi, the second active strategic product, a cancer vaccine currently evaluated in phase 3 for lung cancer non-small cell lung cancer.
Reported by OSE Immunotherapeutics
Presence & Recognition
OSE Immunotherapeutics is hosting a webcast on Tuesday, September 2, at 18:00, featuring international experts from inflammatory diseases of the intestine (MICI).
Reported by OSE Immunotherapeutics
Presence & Recognition
OSE Immunotherapeutics announced that Thomas Gidoin, the Adjunct General Director, was interviewed by BFM Business on behalf of the company during a webinaire about Lusvertikimab, its product in inflammatory bowel disease with international medical professionals.
Reported by Marc Le Bozec
Presence & Recognition
OSE Immunotherapeutics is hosting a KOL webcast on Wednesday, September 2, 2026, featuring international experts Laurent Peyrin-Biroulet and Maia Kayal alongside Marc Le Bozec and Aurore Morello.
Reported by OSE Immunotherapeutics